Apellis pulls its IPO as biotech bears rampage on Wall Street

Editas ($EDIT) and BeiGene ($BGNE) may have made it to Nasdaq, but the IPO window isn't open for everyone. Apellis pulled their attempt at going public. The Kentucky biotech had filed for an $86 million offering last fall, as the market began to unwind. Analysts expect that the bar for completing an IPO of any kind has been raised high in the first half of 2016, as biotech shares in particular have come in for a beating. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.